News >

Immunotherapy Advances SCLC Paradigm, But More Work to Be Done With Combos

Kristi Rosa
Published: Thursday, Jun 13, 2019

Neal E. Ready, MD, PhD

Neal E. Ready, MD, PhD

The biggest advancement seen in small cell lung cancer (SCLC) in recent years was the data that came from the phase III IMpower133 trial, which showed that the addition of atezolizumab (Tecentriq) to chemotherapy led to a statistically significant improvement in overall survival (OS), said Neal E. Ready, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x